SHTDF — Sinopharm Co Balance Sheet
0.000.00%
Last trade - 00:00
- $6.87bn
- $21.71bn
- CNY596.57bn
- 85
- 99
- 17
- 74
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | HKAS | HKAS | HKAS | HKAS | HKAS |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 39,192 | 50,217 | 43,541 | 55,327 | 63,814 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 126,563 | 149,448 | 176,273 | 175,733 | 189,797 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 230,000 | 267,610 | 290,922 | 319,406 | 336,835 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 18,063 | 18,896 | 19,408 | 19,647 | 19,898 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 269,888 | 311,237 | 335,412 | 364,775 | 383,395 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 178,425 | 203,977 | 219,307 | 234,963 | 241,491 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Deferred Income Tax | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 222,466 | 254,878 | 273,526 | 296,707 | 308,813 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Unrealized Gain / Loss | |||||
Total Equity | 47,422 | 56,359 | 61,886 | 68,069 | 74,582 |
Total Liabilities & Shareholders' Equity | 269,888 | 311,237 | 335,412 | 364,775 | 383,395 |
Total Common Shares Outstanding |